ingestion rapidly increases renal electrolyte excretion in humans. J. Appl. Physiol. 88: 540-550, 2000.-This paper describes and quantifies acute responses of the kidneys in correcting plasma volume, acid-base, and ion disturbances resulting from NaHCO 3 and KHCO 3 ingestion. Renal excretion of ions and water was studied in five men after ingestion of 3.57 mmol/kg body mass of sodium bicarbonate (NaHCO 3 ) and, in a separate trial, potassium bicarbonate (KHCO 3 ). Subjects had a Foley catheter inserted into the bladder and indwelling catheters placed into an antecubital vein and a brachial artery. Blood and urine were sampled in the 30-min period before, the 60-min period during, and the 210-min period after ingestion of the solutions. NaHCO 3 ingestion resulted in a rapid, transient diuresis and natriuresis. Cumulative urine output was 44 Ϯ 11% of ingested volume, resulting in a 555 Ϯ 119 ml increase in total body water at the end of the experiment. The cumulative increase (above basal levels) in renal Na ϩ excretion accounted for 24 Ϯ 2% of ingested Na ϩ . In the KHCO 3 trial, arterial plasma K ϩ concentration rapidly increased from 4.25 Ϯ 0.10 to a peak of 7.17 Ϯ 0.13 meq/l 140 min after the beginning of ingestion. This increase resulted in a pronounced, transient diuresis, with cumulative urine output at 270 min similar to the volume ingested, natriuresis, and a pronounced kaliuresis that was maintained until the end of the experiment. Cumulative (above basal) renal K ϩ excretion at 270 min accounted for 26 Ϯ 5% of ingested K ϩ . The kidneys were important in mediating rapid corrections of substantial portions of the fluid and electrolyte disturbances resulting from ingestion of KHCO 3 and NaHCO 3 solutions.
IN ATTEMPTS TO IMPROVE short-term, high-intensity exercise performance, NaHCO 3 loading has long been used (19) . There is, however, little information regarding the time course and magnitude of acute renal responses in humans who have ingested an amount of NaHCO 3 that may be considered to be of ergogenic benefit (minimum of 0.3 g/kg body mass). The chronic responses to ingested or infused bicarbonate solutions in clinical situations have been extensively documented (2, 9, 14, 23, 30, 37) . Few studies, however, have examined the effects of ingested KHCO 3 (37, 38) , and there do not appear to be studies that have compared the early renal responses to large, equimolar doses of NaHCO 3 (sufficient to be of ergogenic benefit in humans, see Ref. 27) and KHCO 3 in humans. The physicochemical origins of plasma fluid and ion disturbances to ingested Na ϩ and K ϩ are expected to be different due to differences in their distribution and cellular transport in the intestine, kidneys, muscles, and other tissues (27) . The bulk of Na ϩ absorbed from the intestinal tract remains in the extracellular fluids (ECFs) and, if not fully excreted, will result in an increased ECF volume (ECFV); on the other hand, K ϩ rapidly enters intracellular fluid compartments (27) .
Although acute effects of KHCO 3 ingestion have not been extensively studied in humans (27, 37, 38) , a generalized comparison of the responses to NaHCO 3 and KHCO 3 may be obtained from various studies. Renal responses to ingested or infused NaHCO 3 or NaCl and KHCO 3 or KCl include increased excretion of the cation and water and a decreased reabsorption of HCO 3 Ϫ (2, 30, 37) . There are, however, some notable differences among responses, depending on the cation (Na ϩ vs. K ϩ ) and the accompanying anion (Cl Ϫ or HCO 3 Ϫ ). NaHCO 3 loading, compared with NaCl loading, results in increased renal excretion of K ϩ (U K ϩV) (14) and Na ϩ (U Na ϩV) (22) , whereas NaCl loading has no effect on U K ϩV and Cl Ϫ excretion (37) . KCl loading, compared with NaCl loading, results in an increased glomerular filtration rate (GFR) (29) , increased plasma aldosterone (30) , and increased renal U K ϩV and Cl Ϫ excretion (24, 30, 37, 38) . KCl loading is also associated with decreases in plasma volume (PV) and ECFV (3, 37) . KHCO 3 loading, compared with KCl loading, results in a prolonged period of urine alkalinization associated with increased HCO 3 Ϫ and Cl Ϫ excretion and decreased excretion of NH 4 ϩ (U NH 4 ϩV) and titratable acid (TA) (37) . The main purposes of this paper are to describe and interpret the acute renal contribution to the correction of the volume, acid-base, and ion disturbances resulting from NaHCO 3 and KHCO 3 loading in humans. An aim of this paper is to integrate the renal responses with the vascular and skeletal muscle responses described previously in these subjects (27) . The hypothesis was tested that the kidneys play an important role in the acute correction of fluid and ion disturbances resulting from NaHCO 3 and KHCO 3 ingestion. It was also hypothesized that in the NaHCO 3 trial, compared with the KHCO 3 trial, the kidneys would excrete excess water, solute, and base equivalents at a greater rate, resulting in a more rapid correction of the fluid and ion disturbance. This study also analyzed urine composition with respect to the independent variables of acidbase control in biological fluids, namely the strong ion difference (SID) concentration ([SID]), the total concentration of weak acids and bases ([A tot ]), and the concentration of CO 2 (28, 35) . These three variables determine the measured concentrations of H ϩ and HCO 3 Ϫ ([H ϩ ] and [HCO 3 Ϫ ], respectively), and analysis of changes in these variables provides insight as to the mechanisms of acid-base control.
METHODS
Five healthy men (age 29 Ϯ 2 yr, mass 80 Ϯ 5 kg) participated in this study. Written informed consent was obtained after the procedures and potential risks were fully described to the subjects. The study was approved by the University's human ethics committee. A sixth subject was treated for hyperkalemia (see Ref. 27) ; this individual's data were excluded from the experiment.
Experimental protocol. In the 24-h period before each trial, subjects abstained from caffeine and alcohol. About 2 h before their arrival at the laboratory, the subjects ate a light meal (toasted bread and juice). All experiments began at ϳ8:00 AM and consisted of ϳ1 h of preparation time and 5 h of data collection.
A brachial artery and antecubital vein (opposite arms) were catheterized percutaneously with a 20-gauge 1.25-in.-long Teflon catheter (Angiocath, Becton Dickinson, Baxter, Mississauga, ON) after the skin was infiltrated with 0.5 ml of 2% Xylocaine without epinephrine (Astra Pharma, Mississauga, ON). The patency of the catheter was maintained using a slow saline drip (ϳ200 µl/min). The urinary tract was infiltrated aseptically with Xylo-Gel (Astra Pharma) and a Foley urinary catheter (Baxter) inserted into the bladder. The urinary analgesic Pyridium (Parke-Davis, Scarborough, ON) was prescribed for 1-3 days following each experiment.
After insertion of the catheters, each subject was seated in a comfortable chair for the remainder of the experiment. During a 30-min baseline period, urine and blood samples were obtained at 15-min intervals. At the end of this period (time 0), subjects ingested 3.57 mmol/kg body mass of either KHCO 3 or NaHCO 3 during the next 60 min. The ϳ920 ml of solution ingested, which had an osmolarity of ϳ600 mosmol/l, was flavored with Kool-Aid and sweetened with Nutrasweet. The order of presenting the experimental treatments was randomized for each trial, and trials were separated by at least 2 wk to allow for normalization of hemoglobin concentration. The subjects were observed for a further 210 min in the postingestion period. Urine drained continuously into a sealed collection bag and was completely collected at 20-min intervals until 120 min and then at 30-min intervals until 270 min.
Measurements and analysis. Arterial and venous blood sampling and analysis have been described (27) . Arterial plasma aldosterone concentration was determined by RIA (Coat-A-Count TKAL1, Diagnostics Products, Los Angeles, CA). Urine TA minus bicarbonate concentration ([TAϪHCO 3 Ϫ ]) was determined by using a double titration procedure (20) as described previously (28) . Briefly, immediately after collection, a 15-ml sample of urine was acidified to below pH 5 with 20 µl of concentrated (60%) nitric acid. The titration was performed on 1.0-ml urine samples by using pH and reference electrodes (MI-406, MI-403, Microelectrodes, Londonderry, NH) with a digital pH meter (PHM 73, Radiometer, Copenhagen, Denmark). Humidified room air (23.6 Ϯ 0.1°C) was bubbled through the urine samples for 15 min to complete the removal of HCO 3 Ϫ from solution. A digital micrometer syringe (model S4200A, Roger Gilmont Instruments, Great Neck, NY) was used to dispense 0.1 N NaOH to titrate the sample back to the corresponding arterial plasma pH.
Calculations. Urine [TAϪHCO 3 Ϫ ] was calculated after Hills (20) 
where EPBTV is the end-point base titration volume (liters), or the volume of base added to reach the desired pH end point; N b and N a are the normality of NaOH and HNO 3 ; V u is the volume of urine titrated (liters); and V a is the volume of HNO 3 added (liters) to remove the HCO 3 Ϫ . Net acid excretion was calculated as U Na 4 ϩV ϩ TAϪHCO 3 Ϫ excretion (U TAϪHCO 3 ϪV).
Creatinine clearance was used as an estimate of GFR and was calculated as previously described (36) . In normal subjects, during the time of day when the study was conducted (8 AM to 1 PM), creatinine clearance reportedly exceeded GFR by a nearly constant 12 Ϯ 2 ml/min (mean Ϯ SE, n ϭ 14; Ref. 36) . Therefore, the small tubular secretion of creatinine is not expected to affect the time course of the observed responses in the present study. Ion excretion rates and ion fractional excretions were calculated with standard equations (36) .
Cumulative electrolyte excretion was determined by integration of ion excretion rates over time. Basal electrolyte excretion was calculated on the basis of the preingestion excretion rates. The difference between total cumulative and cumulative basal excretion was referred to as ''extra'' and represents the amount of ion excreted in excess of basal levels.
Urine [SID] was calculated as the sum of the strong cations minus the sum of the strong anions (35) [
Urine [A tot ] and [HCO 3 Ϫ ] were calculated according to the following equation, which is consistent with the mass action equilibria and electroneutrality of solutions (35) [
where at 37°C the constants have the following values: K A ϭ 1.58 ϫ 10 Ϫ7 eq/l (the dissociation constant for the phosphate buffer system; Ref. 18 ), K C ϭ 2.45 ϫ 10 Ϫ11 (eq/l) 2 /mmHg (35) , K 3 ϭ 6.0 ϫ 10 Ϫ11 eq/l (11) and KЈ W ϭ 4.4 ϫ 10 Ϫ14 (eq/l) 2 (18 Water balance, GFR, and UFR. In the NaHCO 3 trial, there was no change in plasma volume during the ingestion period, and then plasma volume progressively increased, peaking at 7.5 Ϯ 2.0% above initial levels at 210 min (Table 1 ). In contrast, in the KHCO 3 trial, ingestion of the solution resulted in an immediate and pronounced decrease in plasma volume that reached a Table 1 . Plasma ions and percent change in plasma volume before (time 0), during (20, 40 , and 60 min), and after ingestion of NaHCO 3 
Values are means Ϯ SE; n ϭ 5. Ion concentrations are in meq/liter. %dPV, percent change in plasma volume. Brackets denote concentration. * Significantly different from time 0, P Յ 0.05; † KHCO 3 mean significantly different from NaHCO 3 mean, P Յ 0.05. nadir of Ϫ14.9 Ϯ 1.7% below initial levels at 120 min; this was followed by a slow, significant partial recovery. Water balance summaries (Table 2 ) are based on estimates of complete intestinal absorption of the solutions by 270 min (see Ref. 27 ). The net increase in total body water in the NaHCO 3 trial was 555 Ϯ 119 ml, compared with complete restoration of fluid balance (25 Ϯ 83 ml) in the KHCO 3 trial. In the NaHCO 3 trial, the ECF compartment was in positive fluid balance, consistent with the retention of Na ϩ in the ECF compartment (27) . In contrast, in the KHCO 3 trial, ECFV was estimated to be in negative balance by about 800 ml, consistent with a net movement of water into cells (27) .
In the NaHCO 3 trial, initial GFR was 90 Ϯ 18 ml/min and did not change throughout the experiment ( Fig.  2A) . In contrast, in the KHCO 3 trial, GFR increased rapidly from 71 Ϯ 16 ml/min (time 0) to 306 Ϯ 45 ml/min by 60 min and remained elevated until 120 min.
In the NaHCO 3 trial, UFR increased two-to threefold from 0.6 Ϯ 0.2 ml/min (time 0) to 2.6 Ϯ 0.4 ml/min between 80 and 120 min (Fig. 2B) . After KHCO 3 ingestion, UFR increased up to eightfold greater than initial within 80 min and remained significantly greater than in the NaHCO 3 trial until 150 min.
Sodium. In the NaHCO 3 trial, 270 min after ingestion of 280 meq of Na ϩ was begun, 10% of ingested Na ϩ remained in the plasma compartment, 46% remained in the interstitial fluid compartment, and renal U Na ϩV accounted for 30% of ingested Na ϩ (Table 3 ).
In the NaHCO 3 trial, urine [Na ϩ ] increased twofold between the end of ingestion (123 Ϯ 27 meq/l at 60 min) and 270 min (255 Ϯ 14 meq/l). U Na ϩV was threeto fourfold greater than initial values between 80 and 180 min, and it remained elevated (298 Ϯ 14 µeq/min) at 270 min compared with initial levels Values are means Ϯ SE; n ϭ 5. Fluid ingested, fluid volume accompanying the NaHCO 3 or KHCO 3 dose; saline infused, measured from iv drip at 270 min; blood sampling, estimated blood volume loss due to blood sampling; urine volume, cumulative urine volume produced. ⌬PV, change in arterial plasma volume; ⌬ISFV, change in interstitial fluid volume; ⌬ECFV, change in extracellular fluid volume; ⌬TBW, change in total body water. The change in ECFV was partitioned between the changes in PV and ISFV. Minus sign indicates decrease in volume. * KHCO 3 mean significantly different from NaHCO 3 mean, P Ͻ 0.05. (78 Ϯ 21 µeq/min; Fig. 3A) . The fractional excretion of Na ϩ increased fourfold by 120 min, and the mean cumulative fractional excretion was approximately twofold greater than baseline after NaHCO 3 ingestion (Fig. 3B) .
In the KHCO 3 trial, urine [Na ϩ ] did not change and was lower than in the NaHCO 3 trial between 60 and 270 min (not shown). With KHCO 3 ingestion, U Na ϩV increased rapidly and was greater than initial levels between 60 and 120 min and then declined toward initial values by 180 min (Fig. 3A) . Between 60 and 120 min, U Na ϩV was greater in the KHCO 3 than in the NaHCO 3 trial. There was no significant change in the fractional excretion of Na ϩ (Fig. 3B) .
Potassium. In the NaHCO 3 trial, urine [K ϩ ] remained unchanged at ϳ104 Ϯ 16 meq/l (not shown); excretion and the fractional excretion of K ϩ also did not change (Fig. 3, C and D) . In contrast, in the KHCO 3 trial, urine [K ϩ ] increased rapidly from 77 Ϯ 19 meq/l at 120 min to 241 Ϯ 37 meq/l at 270 min. This increase was accompanied by a sixfold increase in U K ϩV between 120 and 180 min (Fig. 3C) and an elevated K ϩ fractional excretion to 71 Ϯ 12% of the filtered load in the last 30 min of the experiment (Fig. 3D) . In the KHCO 3 trial, of the 281 meq of K ϩ ingested, the increase in ECF K ϩ content only accounted for 3%, whereas net K ϩ flux into tissues accounted for 37% (Table 3) . Over the 270 min of the experiment, increased (above basal) U K ϩV accounted for 26 Ϯ 5% of the ingested K ϩ or 76% of the total cumulative U K ϩV of 93 Ϯ 16 meq (Table 3) .
Chloride. In the NaHCO 3 trial, urine [Cl Ϫ ] decreased from 186 Ϯ 16 meq/l at 0 min to 40 Ϯ 7 meq/l at 120 min, with no change in Cl Ϫ excretion or fractional excretion (Fig. 3, E and F) . excretion between 60 and 120 min (Fig. 3E) . Cl Ϫ fractional excretion did not change significantly in either trial, although Cl Ϫ fractional excretion was greater in the KHCO 3 trial than in the NaHCO 3 trial between 80 and 270 min (Fig. 3F) .
Calcium, P i , and lactate. In both trials, urine [Ca 2ϩ ] decreased two-to threefold from 3.6 Ϯ 0.6 meq/l at 0 min to between 1 and 2 meq/l from 80 and 270 min, with no difference between trials. Renal Ca 2ϩ excretion and Ca 2ϩ fractional excretion did not change from initial values (3 Ϯ 1 µeq/min and 1.7 Ϯ 0.7%, respectively) in either trial, with no difference between treatments.
In the NaHCO 3 trial, urine [P i ] remained unchanged at about 24 Ϯ 4 mmol/l. In the KHCO 3 trial, urine [P i ] decreased threefold (from 26 Ϯ 13 mmol/l) at time 0 to 4.3 Ϯ 1.6 mmol/l within 80 min and remained low thereafter. P i excretion did not change (20 Ϯ 9 µmol/ min) in either treatment, with no difference between trials.
Urine lactate Ϫ concentration was initially 0.02 Ϯ 0.01 meq/l in both trials, and in both trials it approached zero by 270 min (not shown).
[SID], pH, and [H ϩ ]. In the NaHCO 3 trial, urine [SID] increased rapidly until 80 min and then increased slowly until the end of the experiment (Fig. 4A ). In the KHCO 3 trial, urine [SID] increased gradually and was greater than initially between 180 and 270 min, but it remained 125-175 meq/l lower than in the NaHCO 3 trial.
In both trials, the magnitude and time course of increase in urine pH were similar, with nadirs reached at 80 min; there were no differences between trials (Fig.  4B ). In the NaHCO 3 (35) . The dashed line fits the data well, supporting the assumption that urine PCO 2 was similar to arterial PCO 2 . The relationship also shows that acidification by CO 2 was pronounced at low and negative urine [SID] (before bicarbonate ingestion) and minor when [SID] was Ͼ100 meq/l (after the start of bicarbonate ingestion). The small amount of weak acids present in urine did not contribute substantially to the relationship (35) .
TA, NH 4 ϩ , and net acid excretion. In both trials, there were large and rapid decreases in urine [TAϪHCO 3 Ϫ ], U TAϪHCO 3 ϪV, and net acid excretion (Fig. 5) . Urine [TAϪ HCO 3 Ϫ ] was significantly decreased from initial values by 80 min in both trials, with similar magnitudes and time course of change (Fig. 5A) . The associated large and rapid decrease in U TAϪHCO 3 ϪV (Fig. 5B) represented a pronounced net excretion of titratable base between 80 and 180 min; there was no difference between trials.
In both trials, urine [NH 4 ϩ ] decreased sevenfold by 100 min, with no difference between trials (Fig. 5D ) U NH 4 ϩV did not change in either trial (Fig. 5D ). Urine net acid concentration (Fig. 5E ) and net acid excretion (Fig. 5F ) were quantitatively similar to that for TAϪ HCO 3 Ϫ , because U NH 4 ϩV formed only a small (1-3%) proportion of total acid excretion. In the NaHCO 3 trial, an amount equivalent to 23 Ϯ 3% of the ingested base was excreted, whereas in the KHCO 3 trial the base excreted accounted for 25 Ϯ 3% of that ingested.
DISCUSSION
This appears to be the first study to compare the acute renal responses to large, equimolar doses (3.57 mmol/kg body mass) of ingested NaHCO 3 and KHCO 3 in humans and in mammals in general. The dose of NaHCO 3 used is sufficient to be of ergogenic benefit (19) , but this dose of KHCO 3 was three to four times greater than that used in previous studies. Earlier studies focused on longer term responses and therefore missed the rapidity with which the kidneys respond to large fluid and electrolyte loads. Furthermore, the ingested Na ϩ and K ϩ resulted in marked differences in renal fluid and ion excretion, consistent with differences in intestinal Na ϩ and K ϩ absorption and differences in the distribution of these cations within body fluid compartments. It is noteworthy that, despite such differences, there was little difference in the renal excretion of base between the two treatments.
Urine acid-base status. Stewart (35) TA refers to the amount of secreted acid titrated by nonvolatile buffers, i.e., weak acids, in the tubular lumen and subsequently excreted as fixed acid. P i with an apparent pKЈ ϭ 6.8 accounts for most of the TA content of the urine (20, 35) . In classical renal physiology, acid is excreted in the urine as NH 4 ϩ and TA, so that net acid excretion equals NH 4 ϩ ϩ TA Ϫ HCO 3 Ϫ excretion. An unexpected result was the marked similarity in renal base excretion in both trials despite the marked differences in rate and magnitude of plasma fluid and ion disturbances and differences in renal water and ion handling (see below). The rate of renal base excretion, however, paralleled that of arterial alkalinization, of which changes in plasma [SID] were the primary determinant (27 In addition, urine [Cl Ϫ ] was greater throughout the KHCO 3 trial. Urine [SID] increased by ϳ175 meq/l greater in the NaHCO 3 trial than in the KHCO 3 Fig.  4C ), consistent with the fact that arterial, and hence renal, PCO 2 (not shown) changed little in both trials.
An increase in urine [A tot ] also contributed to the measured urine [H ϩ ]. In both trials large decreases in [TAϪHCO 3 Ϫ ] were largely independent of changes in urine [P i ], with urine [P i ] only accounting for a small fraction of [TAϪHCO 3 Ϫ ]. As previously described (8), this suggests that there was an increased excretion of weak acids and bases, but their identity and contributions are not known in the present study. The contribution of NH 4 ϩ to net acid excretion was small (1-3%), consistent with a previous report of decreased U NH 4 ϩV after KHCO 3 and KCl ingestion (37) .
In the present study, and in that by Van Buren et al. (37) , much of the decrease in net acid excretion would be classically described as due to increased excretion of HCO 3 Ϫ . This characterization is consistent with an apparent 40% reduction in tubular HCO 3 Ϫ reabsorption in rats with acute metabolic alkalosis (33) and with studies showing that loading with KHCO 3 , NaHCO 3 , KCl, and NaCl results in decreased renal HCO 3 Ϫ reabsorption and decreased urine [H ϩ ] in dogs (29) and humans (2, 37). In addition, there is also evidence that electrogenic proton secretion is reduced in rat nephrons as soon as 3 h after the onset of NaHCO 3 loading (24) . This is consistent with the large, transient decreases in TA (37) and TAϪHCO 3 Ϫ (present study) excretion observed 1-3 h after K ϩ loading in humans.
Water balance. Ingestion of NaHCO 3 resulted in a prolonged retention of fluid with total cumulative urine volume accounting for only 44% of ingested volume. An estimated 56% of ingested Na ϩ remained in the ECF compartment at the end of the experiment (Table 3) consistent with the nearly 1-liter expansion of ECFV (27) . Increases in the delivery of Na ϩ , K ϩ , and base, i.e., increased osmolal clearance, to the distal tubules, without concomitant change in GFR, suggest that decreased tubular fluid reabsorption occurred in association with increased distal tubule Na ϩ delivery. The increase in UFR, however, was largely normalized 2 h after ingestion of the solution, indicating that there was a decreased sensitivity of the volume regulatory system or some feed-forward mechanism to prevent overadjustment in terms of water excretion and U Na ϩV.
In contrast, ingestion of KHCO 3 resulted in a rapid and pronounced decrease in plasma volume that was attributed to an initial rapid net movement of fluid into the proximal small intestine to bring intestinal contents toward plasma osmolarity, with subsequent absorption of water and K ϩ in more distal portions of the small intestine (27) . Despite the ϳ0.5-liter reduction in plasma volume, UFR increased two-to threefold more than in the NaHCO 3 trial, and there were rapid, fourfold increases in GFR and excretion of Na ϩ , Cl Ϫ , and K ϩ .
The magnitude of increase in GFR in response to KHCO 3 ingestion appears to be without precedence in the literature. One study on humans reported no change in GFR in the second hour after oral ingestion of a small amount (1 mmol/kg body mass) of KCl (37) . Modest increases (ϩ19 ml/min) in GFR in sheep given KCl have been reported (4), whereas in rats a decrease in GFR occurring one or more hours after K ϩ loading has been reported (6, 7, 40) . Also, earlier studies did not report GFR until at least 1 h after K ϩ loading. From  Fig. 2 , it is evident that the increase in GFR was rapid and transient and had returned to preingestion values within 210 min after KHCO 3 ingestion was completed. It is difficult to provide a mechanistic explanation for the fourfold increase in GFR in the absence of measures of blood pressure, peripheral vascular resistance, and heart rate. It is not likely that KHCO 3 ingestion was associated with marked increases in blood pressure, given that PV decreased markedly, nor with increases in vascular resistance, given that elevated plasma [K ϩ ] has vasodilatory effects. The rapidity and magnitude at which the hyperkalemia ensued, compared with earlier studies (9, 30, 37) , may have induced indirect effects by increasing renal blood flow and thereby contributing to an increase in net filtration pressure and perfusion pressure at the level of the juxtaglomerular apparatus. However, it is unknown if the changes in tubular water and ion handling were due to the increase in GFR or to the increase in filtered K ϩ (7), and further study is required to understand the mechanistic relationships responsible for these observations. Na ϩ excretion. In the NaHCO 3 trial, the rapid and large increases in urine [Na ϩ ], U Na ϩV, and fractional excretion accounted for 24% of ingested Na ϩ , with the bulk of the Na ϩ remaining in the ECF compartment (27) . The increase in U Na ϩV can be attributed to the modest increases in GFR and increased Na ϩ delivery with decreased proximal tubule Na ϩ reabsorption. The primary mechanism for reduced proximal tubule Na ϩ reabsorption is through inhibition of proximal tubular Na ϩ -K ϩ -ATPase (2, 22) , resulting in increased Na ϩ (and water) delivery to the distal tubules. There is also evidence that acute, transient elevations in dietary Na ϩ induce a natriuresis by a dopamine-mediated decrease in proximal tubule Na ϩ -K ϩ -ATPase activity (1) .
In the KHCO 3 trial the hyperkalemia was associated with increased renal U Na ϩV despite the 15% reduction in plasma volume and decrease in plasma [Na ϩ ]. Hyperkalemia has been shown to inhibit Na ϩ and water absorption by the proximal tubule, resulting in a diuresis and natriuresis (6, 7) without change in plasma renin (30, 37, 38) and atrial natriuretic peptide (37) . Increased GFR was associated with elevated distal tubule Na ϩ delivery with minimal increase in Na ϩ fractional excretion. There appears to be minimal evidence for decreased Na ϩ reabsorption in the diuretic and natriuretic responses to KHCO 3 ingestion. This finding is in contrast to the natriuresis that occurs with KCl ingestion (38) , indicating that the accompanying anion plays a role in modulating tubular excretion and reabsorption of Na ϩ (22) . The later decline in renal U Na ϩV (from 120 min onward) is attributed to the strong antinatriuretic action of aldosterone and the ensuing increase in tubular Na ϩ reabsorption (31, 37, 38, 41) . This effect and associated decreases in GFR, UFR, and Cl Ϫ excretion are consistent with the effects of aldosterone occurring 1-2 h after it begins to increase in the blood (12, 41) . It is concluded that a K ϩ -stimulated natriuresis was responsible for the observed hyponatremia.
K ϩ excretion. NaHCO 3 ingestion resulted in a small, although not statistically significant, increase in U K ϩV, a tendency (Fig. 4) that was associated with a modest hypokalemia. A tendency (P Ͻ 0.1) toward increased U K ϩV is consistent with increased delivery and net reabsorption of Na ϩ , but not Cl Ϫ , at the distal tubules; this tendency establishes a negative electrochemical gradient that favors modest increases in U K ϩV (16, 39) . Alkalosis has also been reported to stimulate Na ϩ -K ϩ -ATPase-mediated uptake of K ϩ into principal cells, resulting in enhanced K ϩ secretion (34) . An increased delivery of HCO 3 Ϫ to the distal nephron, in the presence of increased aldosterone, may also stimulate U K ϩV during alkalosis (34) .
In the KHCO 3 trial, increased excretion of K ϩ above basal levels accounted for 26 Ϯ 5% of ingested K ϩ . Over the course of the experiment, total U K ϩV accounted for 34 Ϯ 6% (about 1.2 mmol/kg) of ingested K ϩ , representing about 17% of the normal kidneys' daily capacity of 7 mmol/kg (31) . The incomplete renal excretion of all ingested K ϩ agrees with the observation that about 64% of ingested K ϩ had entered cells by 270 min and was thus removed from the ECF and the circulatory system (27) .
The rapid, fivefold increase in renal U K ϩV was biphasic in time course, peaking at 90 min before decreasing (Fig. 3C) , and paralleled increases in plasma [K ϩ ] and aldosterone concentration (Fig. 1) . The early rise in U K ϩV preceded the kaliuretic action of increased plasma aldosterone concentration but coincided with the increase in filtered K ϩ load, perhaps indicating a direct kaliuretic effect of increased plasma [K ϩ ] (30). In contrast, the fractional excretion of K ϩ progressively increased over time, peaking at 71 Ϯ 12% of the filtered load at 270 min, consistent with the peak effects of aldosterone occurring 1-2 h after it increases (12, 41) . These results are consistent with previous studies of K ϩ loading in humans (9, 30, 37, 38) and other animals (3, 6, 7, 21, 32, 41) . It is likely that elevated plasma [K ϩ ] and aldosterone concentration independently contributed to the kaliuresis (9, 31) by increasing principal cell Na ϩ -K ϩ -ATPase activity (34) and intracellular [K ϩ ] in the distal tubule and cortical collecting duct (13, 15) . Also, the presence of anions that are relatively impermeant to distal tubule reabsorption (such as bicarbonate and sulphate) increases luminal electronegativity and may have contributed to the increase in K ϩ secretion (39) . An increased flow of fluid through the distal tubule and cortical collecting duct also stimulates K ϩ secretion by these segments (16, 26) .
Cl Ϫ excretion. In the NaHCO 3 trial, as may be expected with increased HCO 3 Ϫ delivery to the tubules, there occurred a 146 meq/l decrease in urine [Cl Ϫ ] and a modest increase (not statistically significant but appearing to be of physiological importance) in tubular Cl Ϫ reabsorption (Fig. 3F) . This response is similar to that seen occurring after acute lactate Ϫ loading caused by high-intensity exercise (28) ; there appears to be a preferential reabsorption of Cl Ϫ over HCO 3 Ϫ and lactate Ϫ . Overall, though, the NaHCO 3 load had only a small effect on renal Cl Ϫ transport, similar to the absence of effect of NaCl loading on renal Cl Ϫ excretion (17, 37) .
The renal Cl Ϫ response to KHCO 3 ingestion, however, is in marked contrast to that seen in the NaHCO 3 trial. Cl Ϫ excretion markedly increased equimolar with the increased excretion of Na ϩ , resulting in similar cumulative excretions of Cl Ϫ and Na ϩ . Similar responses to KHCO 3 loading in humans have previously been reported (37) , and increased HCO 3 Ϫ delivery has been suggested to reduce net Cl Ϫ reabsorption by the proximal tubules and increase Cl Ϫ excretion (37) . The absence of a similar result in the NaHCO 3 trial may be explained by the absence of the rapid and very large increase in GFR seen in the KHCO 3 trial. Thus the marked increases in both Cl Ϫ and Na ϩ excretion seen after KHCO 3 ingestion appear to be associated with mechanisms for acute regulation of plasma [K ϩ ] (10, 25, 37). The decrease in Cl Ϫ excretion late in the experiment (180-270 min) was similar to that seen for Na ϩ and is consistent with Na ϩ -dependent Cl Ϫ absorption mechanisms responding to elevated plasma aldosterone concentration (10, 17) .
Renal Ca 2ϩ and P i regulation. The ingestion of NaHCO 3 and KHCO 3 did not significantly affect renal Ca 2ϩ and P i excretion. In both trials, the decreases in urine [Ca 2ϩ ] and [P i ] were due solely to the accompanying diuresis, consistent with the absence of significant change in plasma Ca 2ϩ content (27) .
Implications for exercise performance. NaHCO 3 loading is widely practiced in human and equine athletic competition as a means of reducing the severity of extra-and intracellular acidosis resulting from the performance of high-intensity exercise (19) . Indeed, the dose of NaHCO 3 administered in the present study consistently results in performance-enhancing effects in humans (19) . It is also noteworthy that NaHCO 3 loading resulted in an ϳ1-liter expansion of plasma volume that persisted in excess of 3 h after ingestion of the solution. This result indicates that the gastrointestinal tract may be used as a reservoir of readily available water and Na ϩ for maintaining extracellular volume during prolonged exercise. On the negative side, there was a twofold increase in UFR during the first 2 h after ingestion that may compromise exercise performance.
High-intensity exercise results in the rapid loss of K ϩ from contracting skeletal muscle, and the resulting decrease in intracellular [K ϩ ] is thought to contribute to skeletal muscle fatigue (see Ref. 27) . The rationale for providing subjects with oral KHCO 3 , at a dose equivalent to the performance-enhancing effect of NaHCO 3 , was twofold. The first was to provide a similar magnitude alkalosis to offset exercise-induced acidosis, with the idea that K ϩ being predominantly intracellular would provide further protection against intracellular acidosis. The second was to provide additional K ϩ to skeletal muscles so as to better maintain intracellular [K ϩ ] and delay the onset of fatigue in the face of contraction.
However, the results of the present study indicate that KHCO 3 loading should not be considered for the enhancement of exercise performance. Ingestion of this quantity of K ϩ poses safety concerns, both at rest and particularly if subjects are contemplating exercise. Ingestion of more than 150 mmol (about 16 g) of KHCO 3 results in a rapid increase in plasma [K ϩ ] that may require prompt treatment for hyperkalemia (see Ref. 27) . Two hours after ingestion of KHCO 3 , subjects maintained an average plasma [K ϩ ] of about 6 meq/l, which, with high-intensity exercise, could result in life-threatening increases in plasma [K ϩ ]. Also, it is likely that the rapid and pronounced decrease in plasma volume that occurred with KHCO 3 ingestion may impose additional stress on the cardiovascular and intestinal systems during exercise.
Conclusions. Renal responses to ingested NaHCO 3 and KHCO 3 solutions are more rapid and of greater magnitude than previously appreciated. In both trials, excreted Na ϩ and K ϩ accounted for 25-40% of the ingested ion and, in the KHCO 3 trial, cumulative urine volume over 270 min equaled the ingested volume load. In both trials, the GFR and UFR responses were transient and largely normalized by 210 min postingestion. The neural and cellular mechanisms for the rapid up-and downregulation of GFR and UFR in the NaHCO 3 trial are not well understood. The rapidity of the downregulation suggests either that, after some time, the regulatory systems become tolerant of the remaining fluid imbalance or that there may be feedforward mechanisms for preventing overadjustment of fluid and Na ϩ balance. In the KHCO 3 compared with the NaHCO 3 trial, renal ion excretions occurred with greater rapidity, were of greater magnitude, and resulted in an increased osmotic clearance. In both trials, increases in base excretion were sustained until the end of the experimental period. It is also noteworthy that, although the plasma acid-base disturbances had markedly different physicochemical origins (27) , the renal acid-base responses were similar with respect to excretion of base. The rapidity and magnitude with which the kidneys responded to the NaHCO 3 and KHCO 3 loading demonstrate their capacity, and physiological importance, for restoring body fluid homeostasis in the face of large, acute disturbances in water, ion, and acid-base balance.
